Market Overview
| Study Period | 2019 - 2030 |
|---|---|
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| Historical Data Period | 2019 - 2023 |
| Growth Rate | 10.50% CAGR |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. |
|
Europe Injectable Drug Delivery Market Analysis by Mordor Intelligence
The Europe Injectable Drug Delivery Market is expected to register a CAGR of 10.5% during the forecast period.
The Europe injectable drug delivery market has been significantly impacted by the COVID-19 pandemic due to the development of vaccines and treatment against COVID-19 which has increased the demand for needles and syringes in the market. For instance, according to the European Medicines Agency (EMA), many treatment options and vaccines were approved during the study period. For instance, in December 2021, EMA granted authorization for Novavax's COVID-19 vaccine Nuvaxovid to prevent COVID-19 in people from 18 years of age. Also, in January 2022, EMA's human medicines committee (CHMP) approved a scale-up of manufacturing of Vaxzevria (previously COVID-19 Vaccine AstraZeneca). The scale-up of manufacturing of the vaccines and new approvals shows a positive impact on injectable drug delivery devices like needles and syringes which helps in the growth of the market during the study period.
The major growth drivers of the Europe injectable drug delivery market are the growing burden of chronic diseases and benefits, and convenience in the usage of the injectables. For instance, as per the International Diabetes Federation (IDF) Diabetes Atlas 2021, the age-adjusted comparative prevalence of diabetes in Europe for 2021, 2030, and 2045 were estimated as 7.0%, 8.0%, and 8.7% respectively. There is gradual raise in the prevalence of diabetes in Europe which is expected to increase demand for prefilled syringes and autoinjector-dependent treatments in the forecast period.
However, the growing use of alternative drug delivery methods may restrain market growth over the forecast period.
Europe Injectable Drug Delivery Market Trends and Insights
Self-injectable Drug Delivery Device Segment is Expected to Dominate the Market During the Forecast Period
The major factor attributed to the high growth of the self-injectable drug delivery device segment is the growing burden of chronic disease and the convenience associated with the device. The acceptance of these products has increased over the past few years owing to the advantages of self-injectable injections and increasing awareness of self-administration. Many global and domestic companies have expanded their portfolios in this field, resulting in new and innovative solutions.
For instance, in February 2021, Xeris Pharmaceuticals, Inc. received approval from the European Commission (EC) for Ogluo (glucagon) pre-filled pen for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. Also, in July 2022, European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion and recommended the authorization for the use of Mounjaro (tirzepatide) auto-injector pen for type 2 diabetes. Hence, owing to these factors, the market is expected to grow in the forecast period.
Furthermore, the rise in the burden of chronic diseases drives the growth of the market as injectables are the major drug delivery systems in the treatment of chronic diseases. For instance, according to the report of GLOBOCAN 2020, in Europe, more than 530,000 patients are diagnosed with breast cancer each year and it alone accounts for approximately 29% of all cancers in women. Thus, raise in the chronic diseases increases the usage of self-injectable drug delivery devices like prefilled syringes and auto-injectors which are majorly used in the treatment.
Thus, due to the above-mentioned factors, the self-injectable drug delivery device segment is expected to grow significantly during the forecast period.
United Kingdom Holds a Significant Share in the Market and is Expected to do Same Over the Forecast Period
The United Kingdom contributes a significant share among the Europe countries for injectable drug delivery devices due to the rising number of chronic diseases that may influence the usage of injectables and sophisticated healthcare systems compared with other countries in Europe. For instance, as per the International Diabetes Federation (IDF) Diabetes Atlas 2021, the age-adjusted comparative prevalence of diabetes in the United Kingdom for 2021, 2030, and 2045 were estimated as 6.3%, 7.0%, and 7.5% respectively. This shows a gradual raise in the prevalence of diabetes in the forecast period which is expected to increase demand for self-injectable drug delivery devices.
Furthermore, the developments and authorizations of COVID-19 vaccines and treatments in the United Kingdom help the growth of the injectable drug delivery market during the study period. For instance, in April 2022, The COVID-19 vaccine developed by Valneva received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. Also, in February 2022, Nuvaxovid, the COVID-19 vaccine developed by Novavax received approval from the MHRA in the United Kingdom. This helps in the usage of injectable drug delivery devices which helps in the growth of market.
Thus, due to the above-mentioned factors, the United Kingdom segment is expected to grow significantly in the market during the forecast period.
Competitive Landscape
The Europe injectable drug delivery market is moderately competitive and most of the companies are international players. With the increasing prevalence of diseases, technological advancements, and patient compliance, few other key market players are expected to enter the market in the coming years. Some of the major players include Baxter, Becton, Dickinson and Company, Lilly, Gerresheimer AG, Novo Nordisk A/S, Pfizer Inc., Schott AG, Terumo Corporation, Teva Pharmaceutical Industries Ltd, Recipharm AB, Stevanato Group., and West Pharmaceutical Services, Inc.
Europe Injectable Drug Delivery Industry Leaders
-
Becton, Dickinson and Company
-
Baxter
-
Gerresheimer AG
-
Lilly
-
Teva Pharmaceutical Industries Ltd
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competitors?
Download PDF
Recent Industry Developments
- May 2022: Stevanato Group S.p.A. signed an exclusive agreement with leading medical device developer and manufacturer Owen Mumford Ltd. for its Aidaptus auto-injector. Aidaptus is a 2-step, single-use auto-injector with a versatile design that accommodates both 1 mL and 2.25 mL prefilled glass syringes in the same base device.
- May 2020: Takeda Pharmaceutical Company Limited received approval from the European Commission for the subcutaneous (SC) formulation of Entyvio (vedolizumab), a gut-selective biologic for use as maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD). Entyvio SC is available in both a pre-filled syringe and a pre-filled pen.
Europe Injectable Drug Delivery Market Report Scope
As per the scope of the report, injectable drug delivery devices are specialized tools for the delivery of a drug or therapeutic agent via a parenteral route of administration. The Europe injectable drug delivery market is segmented by Device Type (Conventional Drug Delivery Devices and Self-injectable Drug Delivery Devices [Prefilled Syringes, Injectable Pens, Auto-Injectors, Needle-free Injectors, and Other Device Types]), Therapeutic Application (Cardiovascular Disease, Diabetes, Oncology, Autoimmune Disorders, Hepatitis, and Other Therapeutic Applications), and Geography (Germany, France, United Kingdom, Italy, Spain, and Rest of Europe). The report offers the value (in USD million) for the above segments.
By Devices Type
| Conventional Drug Delivery Devices | |
| Self-injectable Drug Delivery Devices | Prefilled Syringes |
| Injectable Pens | |
| Auto Injectors | |
| Needle-free Injectors | |
| Other Device Types |
By Therapeutic Application
| Cardiovascular Disease |
| Diabetes |
| Oncology |
| Autoimmune Disorders |
| Hepatitis |
| Other Therapeutic Applications |
Geography
| Germany |
| United Kingdom |
| France |
| Italy |
| Spain |
| Rest of Europe |
| By Devices Type | Conventional Drug Delivery Devices | |
| Self-injectable Drug Delivery Devices | Prefilled Syringes | |
| Injectable Pens | ||
| Auto Injectors | ||
| Needle-free Injectors | ||
| Other Device Types | ||
| By Therapeutic Application | Cardiovascular Disease | |
| Diabetes | ||
| Oncology | ||
| Autoimmune Disorders | ||
| Hepatitis | ||
| Other Therapeutic Applications | ||
| Geography | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
Need A Different Region or Segment?
Customize Now
Key Questions Answered in the Report
What is the current Europe Injectable Drug Delivery Market size?
The Europe Injectable Drug Delivery Market is projected to register a CAGR of 10.5% during the forecast period (2025-2030)
Who are the key players in Europe Injectable Drug Delivery Market?
Becton, Dickinson and Company, Baxter, Gerresheimer AG, Lilly and Teva Pharmaceutical Industries Ltd are the major companies operating in the Europe Injectable Drug Delivery Devices Market.
What years does this Europe Injectable Drug Delivery Market cover?
The report covers the Europe Injectable Drug Delivery Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Europe Injectable Drug Delivery Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Page last updated on:
